Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/19/2009WO2009034432A2 Novel compounds active as muscarinic receptor antagonists
03/19/2009WO2009034431A2 Controlled-release dosage forms for varenicline
03/19/2009WO2009034411A1 Perharidines as cdk inhibitors
03/19/2009WO2009034409A2 Pharmaceutical compositions of rhein or diacerein
03/19/2009WO2009034390A1 Heterocyclic derivatives and their use in treating hepatitis c
03/19/2009WO2009034388A1 Compounds for the treatment of metabolic disorders
03/19/2009WO2009034386A1 Derivatives of adenine and 8-aza-adenine and uses thereof-796
03/19/2009WO2009034380A1 Piperidine derivatives as agonists of muscarinic receptors
03/19/2009WO2009034326A1 Phthalazinone derivatives
03/19/2009WO2009034258A1 Tri-amino-pyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors
03/19/2009WO2009034232A1 Preparation and a component intended to be added to a tobacco product
03/19/2009WO2009034216A1 Use of oxoisoaporphines and the derivatives thereof as selective inhibitors of monoamino oxidase a
03/19/2009WO2009034171A1 Pharmaceutical compositions for oral use for treating patients affected by obesity
03/19/2009WO2009034148A1 Liposomal formulations for treating cancer
03/19/2009WO2009034133A1 Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine
03/19/2009WO2009034130A1 Process for preparing thermosensitive (poly(ethylene oxide) poly(propylene oxide)) derivatives that can be used to functionalize chitosan.
03/19/2009WO2009034111A1 Treatment of vasomotor symptoms
03/19/2009WO2009034062A1 Compounds which inhibit the glycine transporter and uses thereof in medicine
03/19/2009WO2009034061A1 Spiro-condensed imidazolone derivatives inhibiting the glycine transporter
03/19/2009WO2009034043A1 Novel phenoxazin-3-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/19/2009WO2009034042A1 Novel benzooxazol- and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/19/2009WO2009034029A2 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists
03/19/2009WO2009034028A2 Novel compounds
03/19/2009WO2009033995A1 Piperidine derivatives as nk3 receptor antagonists
03/19/2009WO2009033706A1 Increasing the in vivo biological activity of biologically active compounds
03/19/2009WO2009033704A1 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
03/19/2009WO2009033703A1 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
03/19/2009WO2009033702A1 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
03/19/2009WO2009033689A1 Piperidone derivatives and medical uses thereof
03/19/2009WO2009033652A1 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus
03/19/2009WO2009033651A1 Titration package for neramexane and its use in the treatment of an inner ear disorder
03/19/2009WO2009033650A1 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
03/19/2009WO2009033649A1 Interval therapy for the treatment of tinnitus
03/19/2009WO2009033581A1 Substituted tricyclic compounds and methods of use thereof
03/19/2009WO2009033561A1 Substituted 6-phenylnicotinic acids and the use thereof
03/19/2009WO2009033505A1 Hellebrin derivatives
03/19/2009WO2009033494A1 1- or 2-substituted artemisinin derivatives for increasing the in vivo biological activity of biologically active compounds
03/19/2009WO2009033489A2 Selective pacl inhibitors for use in the treatment of migraine and headaches
03/19/2009WO2009033396A1 Dithiolopyrrolone compounds, the preparation and the use thereof
03/19/2009WO2009033360A1 Benzamide derivatives, their preparation and uses in medicine thereof
03/19/2009WO2009033326A1 Ascorbic acid derivates, their preparation methods, intermediates and uses in cosmetics
03/19/2009WO2009033305A1 5-ht3 receptor antagonists for the teatment of myocardial infarction, thrombosis and atherosclerosis
03/19/2009WO2009033284A1 Inhibitors of collagen biosynthesis as anti-tumor agents
03/19/2009WO2009033282A1 Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects
03/19/2009WO2009033281A1 Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
03/19/2009WO2009033250A1 Composition and method for increasing the anabolic state of muscle cells
03/19/2009WO2009033204A1 Multi-component compositions and methods for delivery of anti-cancer agents
03/19/2009WO2009023544A3 Dosage unit anion-exchange polymer pharmaceutical compositions
03/19/2009WO2009023539A3 Tetrahydropyridine carboxamide derivatives as trpvl antagonists
03/19/2009WO2009020603A3 Upp amphiphilic alpha-helix mimetics
03/19/2009WO2009018551A3 Therapeutic compounds
03/19/2009WO2009018069A3 Mixtures of cyclodextrin derivatives
03/19/2009WO2009017874A9 Novel curcumin derivatives and their pharmaceutical uses thereof
03/19/2009WO2009017863A3 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
03/19/2009WO2009015812A3 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile
03/19/2009WO2009015446A3 Triazole derivatives as viral replication inhibitors
03/19/2009WO2009015336A3 Controlled release interferon drug products and treatment of hcv infection using same
03/19/2009WO2009015063A3 Methods and compositions for treating fibrosis related disorders using il-17 antagonists
03/19/2009WO2009014637A3 Heterocyclic amide compounds as protein kinase inhibitors
03/19/2009WO2009014372A3 Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof
03/19/2009WO2009013724A3 Trimetal-arene clusters with anticancer activity
03/19/2009WO2009013299A3 Novel bradykinin b1 antagonists
03/19/2009WO2009012359A3 Matrix metalloprotease targeting nucleic acids
03/19/2009WO2009009776A3 Patient selection and therapeutic methods using markers of prostaglandin metabolism
03/19/2009WO2009008980A3 Tetrahydropyranochromene gamma secretase inhibitors
03/19/2009WO2009008913A3 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
03/19/2009WO2009007827A3 Novel diclofenac esters and uses thereof
03/19/2009WO2009007674A3 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
03/19/2009WO2009007673A3 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
03/19/2009WO2009007536A3 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
03/19/2009WO2009007390A3 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
03/19/2009WO2009007348A3 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs
03/19/2009WO2009006567A3 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
03/19/2009WO2009006555A3 Methods, composition, targets for combinational cancer treatments
03/19/2009WO2009006366A3 Weight loss composition
03/19/2009WO2009005646A3 Substituted piperazines as cb1 antagonists
03/19/2009WO2009003669A3 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
03/19/2009WO2009002790A3 Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
03/19/2009WO2009002510A3 Crystalline polymorph of exemestane
03/19/2009WO2009002489A3 Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
03/19/2009WO2009001144A3 Pharmaceutical aerosol compositions comprising fluticasone
03/19/2009WO2008157514A3 Metal ion-treated biocompatible polymers useful for nanoparticles
03/19/2009WO2008157335A3 Methods for the treatment of erectile dysfunction using fispemifene
03/19/2009WO2008155141A3 Novel facultative catonic sterols
03/19/2009WO2008155069A3 Substituted oxazolidinones and use thereof
03/19/2009WO2008153793A3 Gamma secretase modulators
03/19/2009WO2008152226A3 Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof
03/19/2009WO2008150495A3 Vwf aptamer formulations and methods for use
03/19/2009WO2008149379A3 Novel compounds
03/19/2009WO2008147807A3 Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
03/19/2009WO2008147626A3 Thiazoles and pyrazoles useful as kinase inhibitors
03/19/2009WO2008146178A3 A novel tablet dosage form
03/19/2009WO2008146018A3 Drug delivery system comprising matrix metalloproteinase inhibitors
03/19/2009WO2008143916A3 Prokinetic agent for bowel preparation
03/19/2009WO2008141248A3 Thiocarbon-protecting groups for rna synthesis
03/19/2009WO2008138878A3 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
03/19/2009WO2008137619A3 Thiazoles and pyrazoles useful as kinase inhibitors
03/19/2009WO2008135886A3 Quinoline derivatives for use in the inhibition of the growth of tumour cells
03/19/2009WO2008131946A3 Substituted amide derivatives
03/19/2009WO2008131419A3 Glycoconjugates of rna interference agents
1 ... 2816 2817 2818 2819 2820 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 ... 7860